OR WAIT null SECS
© 2021 MJH Life Sciences and Psychiatric Times. All rights reserved.
© 2021 MJH Life Sciences™ and Psychiatric Times. All rights reserved.
September 14, 2021
Decades of efforts to find effective medical treatments for dementia and Alzheimers disease have largely failed. Would a public health approach be more effective?
August 10, 2021
What advice can clinicians give patients to lower their overall risk for neurodegenerative diseases?
August 03, 2021
A new study finds amyloid plaques accelerate the breakup of neurotransmitters, worsening neurodegenerative diseases like Alzheimer disease.
July 30, 2021
More potential good news for treating Alzheimer disease, as an 18-month open-label extension for lecanemab allows for its breakthrough status.
July 23, 2021
Although the new drug aducanumab has grabbed all the headlines, the future of Alzheimer treatment may be just as much about public health campaigns as it is about psychopharmacology. In this episode of Psych Pearls, we find out why.
July 14, 2021
Apathy occurs throughout the spectrum of neurocognitive disorders, but it is easy to mistake for other conditions, like depression. How can clinicians identify apathy, and treat it?
July 08, 2021
Following criticism for its wide-labeled June approval, the FDA has decided to narrow the patient recommendation for aducanumab.
June 28, 2021
How can volunteering to play video games help brain research?
June 25, 2021
Donanemab for the treatment of Alzheimer disease has received Breakthrough Therapy designation from the FDA.
June 16, 2021
The FDA approval of aducanumab has given hope to millions of patients with Alzheimer disease—but will it live up to the hype?